
Amicus Therapeutics, Inc. (FOLD)
Whether directors and officers of Amicus Therapeutics, Inc. (FOLD) breached their fiduciary duties to the company and its shareholders.
Investigation
04/18/2022
Initial Lawsuit
05/06/2022
Lawsuit Progression
07/05/2022
Investors investigation focused on discrepancies between statements made by Arqit and The Wall Street Journal article describing management’s “overly optimistic view”, citing documents and interviews with former staff.
04/18/2022
The Wall Street Journal publishes an article entitled “British Encryption Startup Arqit Overstates Its Prospects, Former Staff and Others Say” following interviews with former employees and other people familiar with the company, and documents. The article describes how the company has given investors “an overly optimistic view” of its prospects, growth and readiness of its technology.
“In April 2021, Arqit’s chief revenue officer resigned after raising concerns with Mr. Williams that he was overstating contracts and giving unrealistic revenue projections to potential investors, people familiar with the matter said. Several other former employees said they had similar concerns about both the business model and the maturity of the technology, prompting them to also leave since then . . .”
“The people familiar with the matter said that the bulk of the company’s committed revenue isn’t from selling its product and that at its public launch, the company had little more than an early-stage prototype of its encryption system. Several clients the company lists—including a number of British government agencies—are simply giving Arqit research grants, nonbinding memorandums of understanding or research agreements that come with no funding, not contracts for its encryption product, they said.”
Stock Impact
Close | Previous close | Price variation | Percentage variation |
---|---|---|---|
$12.49 | $15.06 | $-2.57 | -17.07% |
This is a class action on behalf of: (i) all persons or entities who purchased or otherwise acquired Arqit securities between September 7, 2021 and April 18, 2022, inclusive; and/or (ii) all holders of Centricus securities as of the record date for the special meeting of shareholders held on August 31, 2021 to consider approval of the merger between Arqit and Centricus and entitled to vote on the Merger.
According to the complaint, defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the company’s business, operations, and prospects. Specifically, defendants allegedly failed to disclose to investors that:
(1) Arqit’s proposed encryption technology would require wide spread adoption of new protocols and standards of for telecommunications;
(2) British cybersecurity officials questioned the viability of Arqit’s proposed encryption technology in a meeting in 2020;
(3) the British government was not an Arqit customer but, rather, providing grants to Arqit;
(4) Arqit had little more than an early-stage prototype of its encryption system at the time of the merger between Arqit and Centricus; and
(5) as a result, defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.
The lead plaintiff deadline has passed, we will update this page as the lawsuit progresses.
Last event retrieved on 10/08/2022.
Whether directors and officers of Amicus Therapeutics, Inc. (FOLD) breached their fiduciary duties to the company and its shareholders.
Whether directors and officers of Kewaunee Scientific Corporation (KEQU) breached their fiduciary duties to the company and its shareholders.
Whether directors and officers of Inari Medical, Inc. (NARI) breached their fiduciary duties to the company and its shareholders.
Whether directors and officers of LegalZoom.com, Inc. (LZ) breached their fiduciary duties to the company and its shareholders.
Whether directors and officers of Payoneer Global Inc. (PAYO) breached their fiduciary duties to the company and its shareholders.
Whether directors and officers of Builders FirstSource, Inc. (BLDR) breached their fiduciary duties to the company and its shareholders.